A sequential methodology for the rapid identification and characterization of breast cancer associated functional SNPs.
Nature communications. Forthcoming.
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Clin Cancer Res.
2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. PubMed PMID:
36074155; PubMed Central PMCID:
PMC9811155.
Targeting CDK4 and CDK6 in cancer.
Nat Rev Cancer.
2022 Jun;22(6):356-372. doi: 10.1038/s41568-022-00456-3. Epub 2022 Mar 18. Review. PubMed PMID:
35304604; PubMed Central PMCID:
PMC9149100.
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
Nat Commun.
2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1. PubMed PMID:
35641483; PubMed Central PMCID:
PMC9156717.
Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids.
Nano Lett.
2022 May 25;22(10):4058-4066. doi: 10.1021/acs.nanolett.2c00723. Epub 2022 May 6. PubMed PMID:
35522597; PubMed Central PMCID:
PMC9164000.
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Mol Cancer Res.
2022 May 4;20(5):673-685. doi: 10.1158/1541-7786.MCR-21-0322. PubMed PMID:
35105671; PubMed Central PMCID:
PMC9081176.
p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases.
Nat Commun.
2022 Mar 18;13(1):1473. doi: 10.1038/s41467-022-29081-2. PubMed PMID:
35304445; PubMed Central PMCID:
PMC8933392.
Temporal and spatial topography of cell proliferation in cancer.
Nat Cell Biol.
2022 Mar;24(3):316-326. doi: 10.1038/s41556-022-00860-9. Epub 2022 Mar 15. PubMed PMID:
35292783; PubMed Central PMCID:
PMC8959396.
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake.
Cell Rep.
2022 Mar 15;38(11):110509. doi: 10.1016/j.celrep.2022.110509. PubMed PMID:
35294873; PubMed Central PMCID:
PMC9396916.
Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN.
J Cell Biol.
2022 Feb 7;221(2). doi: 10.1083/jcb.202106080. Epub 2021 Dec 22. PubMed PMID:
34935867; PubMed Central PMCID:
PMC8704956.
How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer.
Cancer Res.
2021 Dec 15;81(24):6074-6077. doi: 10.1158/0008-5472.CAN-21-3605. PubMed PMID:
34911779; PubMed Central PMCID:
PMC9033251.
Disrupted PI3K subunit p110α signaling protects against pulmonary hypertension and reverses established disease in rodents.
J Clin Invest.
2021 Oct 1;131(19). doi: 10.1172/JCI136939. PubMed PMID:
34596056; PubMed Central PMCID:
PMC8483754.
Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling.
Sci Adv.
2021 Jun;7(27). doi: 10.1126/sciadv.abf1068. Print 2021 Jun. PubMed PMID:
34193412; PubMed Central PMCID:
PMC8245041.
The role of the PIK3CA gene in the development and aging of the brain.
Sci Rep.
2021 Jan 11;11(1):291. doi: 10.1038/s41598-020-79416-6. PubMed PMID:
33431926; PubMed Central PMCID:
PMC7801510.
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity.
Nat Cancer.
2021 Jan;2(1):34-48. doi: 10.1038/s43018-020-00135-y. Epub 2020 Nov 9. PubMed PMID:
33997789; PubMed Central PMCID:
PMC8115221.
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.
Clin Cancer Res.
2020 Nov 1;26(21):5557-5566. doi: 10.1158/1078-0432.CCR-19-2300. Epub 2020 Jun 23. Review. PubMed PMID:
32576627; PubMed Central PMCID:
PMC7641965.
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Cell Rep.
2020 Sep 29;32(13):108196. doi: 10.1016/j.celrep.2020.108196. PubMed PMID:
32997991; PubMed Central PMCID:
PMC7571617.
PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
Proc Natl Acad Sci U S A.
2020 Sep 29;117(39):24427-24433. doi: 10.1073/pnas.2000060117. Epub 2020 Sep 14. PubMed PMID:
32929011; PubMed Central PMCID:
PMC7533832.
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Cancer Discov.
2020 Sep;10(9):1352-1373. doi: 10.1158/2159-8290.CD-19-1228. Epub 2020 Jun 22. PubMed PMID:
32571778; PubMed Central PMCID:
PMC7483776.
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.
Sci Adv.
2020 Jun;6(25):eabb2210. doi: 10.1126/sciadv.abb2210. eCollection 2020 Jun. PubMed PMID:
32704543; PubMed Central PMCID:
PMC7360435.
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors.
Sci Signal.
2020 Jun 16;13(636). doi: 10.1126/scisignal.aay1451. PubMed PMID:
32546544; PubMed Central PMCID:
PMC8023011.
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Oncogene.
2020 Jan;39(1):50-63. doi: 10.1038/s41388-019-0953-9. Epub 2019 Aug 28. PubMed PMID:
31462705; PubMed Central PMCID:
PMC6937212.
PI3 kinase alpha and delta promote hematopoietic stem cell activation.
JCI Insight.
2019 May 23;5. doi: 10.1172/jci.insight.125832. PubMed PMID:
31120863; PubMed Central PMCID:
PMC6629136.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
J Clin Oncol.
2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4. PubMed PMID:
30715997; PubMed Central PMCID:
PMC6553812.
Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method.
Sci Rep.
2019 Jan 24;9(1):622. doi: 10.1038/s41598-018-36874-3. PubMed PMID:
30679540; PubMed Central PMCID:
PMC6346002.
Targeted Profiling of RNA Translation.
Curr Protoc Mol Biol.
2019 Jan;125(1):e71. doi: 10.1002/cpmb.71. Epub 2018 Oct 22. PubMed PMID:
30346115; PubMed Central PMCID:
PMC6326074.
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Cell Rep.
2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. PubMed PMID:
30540933; PubMed Central PMCID:
PMC6366450.
A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells.
iScience.
2018 Nov 30;9:149-160. doi: 10.1016/j.isci.2018.10.015. Epub 2018 Oct 18. PubMed PMID:
30391850; PubMed Central PMCID:
PMC6215964.
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Trends Cell Biol.
2018 Nov;28(11):911-925. doi: 10.1016/j.tcb.2018.07.002. Epub 2018 Jul 27. Review. PubMed PMID:
30061045; PubMed Central PMCID:
PMC6689321.
Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo.
J Med Chem.
2018 Oct 11;61(19):8613-8624. doi: 10.1021/acs.jmedchem.8b00498. Epub 2018 Sep 27. PubMed PMID:
30227711; PubMed Central PMCID:
PMC6668024.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation.
Proc Natl Acad Sci U S A.
2018 Oct 9;115(41):E9600-E9609. doi: 10.1073/pnas.1807112115. Epub 2018 Sep 25. PubMed PMID:
30254159; PubMed Central PMCID:
PMC6187201.
Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins.
Proc Natl Acad Sci U S A.
2018 Oct 2;115(40):E9325-E9332. doi: 10.1073/pnas.1805782115. Epub 2018 Sep 17. PubMed PMID:
30224479; PubMed Central PMCID:
PMC6176620.
An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.
Elife.
2018 Jul 30;7. doi: 10.7554/eLife.37184. PubMed PMID:
30059005; PubMed Central PMCID:
PMC6103745.
Oridonin inhibits aberrant AKT activation in breast cancer.
Oncotarget.
2018 May 8;9(35):23878-23889. doi: 10.18632/oncotarget.24378. eCollection 2018 May 8. PubMed PMID:
29844859; PubMed Central PMCID:
PMC5963618.
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer.
J Clin Oncol.
2018 May 1;36(13):1339-1342. doi: 10.1200/JCO.2017.77.0891. Epub 2018 Mar 8. PubMed PMID:
29517943.
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?.
Clin Cancer Res.
2018 Apr 15;24(8):1795-1804. doi: 10.1158/1078-0432.CCR-17-3351. Epub 2018 Feb 6. PubMed PMID:
29437794; PubMed Central PMCID:
PMC5899637.
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
Cancer Cell.
2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004. PubMed PMID:
29438694; PubMed Central PMCID:
PMC5813700.
ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Oncogene.
2017 Oct 26;36(43):6059-6066. doi: 10.1038/onc.2017.264. Epub 2017 Aug 7. PubMed PMID:
28783168; PubMed Central PMCID:
PMC5808977.
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Nature.
2017 Sep 28;549(7673):533-537. doi: 10.1038/nature24014. Epub 2017 Sep 20. PubMed PMID:
28959975; PubMed Central PMCID:
PMC5891832.
MELK is not necessary for the proliferation of basal-like breast cancer cells.
Elife.
2017 Sep 19;6. doi: 10.7554/eLife.26693. PubMed PMID:
28926338; PubMed Central PMCID:
PMC5605198.
CDK4/6 inhibition triggers anti-tumour immunity.
Nature.
2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16. PubMed PMID:
28813415; PubMed Central PMCID:
PMC5570667.
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.
Biochim Biophys Acta Rev Cancer.
2017 Aug;1868(1):123-131. doi: 10.1016/j.bbcan.2017.03.002. Epub 2017 Mar 14. Review. PubMed PMID:
28315368; PubMed Central PMCID:
PMC5548615.
CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.
Cell Rep.
2017 Jul 18;20(3):549-557. doi: 10.1016/j.celrep.2017.06.054. PubMed PMID:
28723560; PubMed Central PMCID:
PMC5704918.
PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Proc Natl Acad Sci U S A.
2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19. PubMed PMID:
28630349; PubMed Central PMCID:
PMC5502636.
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
Cancer Cell.
2017 Apr 10;31(4):576-590.e8. doi: 10.1016/j.ccell.2017.03.004. PubMed PMID:
28399412; PubMed Central PMCID:
PMC5425285.
Tyrosine receptor kinase B is a drug target in astrocytomas.
Neuro Oncol.
2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10. PubMed PMID:
27402815; PubMed Central PMCID:
PMC5193024.
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.
Proc Natl Acad Sci U S A.
2016 Nov 15;113(46):13156-13161. doi: 10.1073/pnas.1604450113. Epub 2016 Oct 31. PubMed PMID:
27799550; PubMed Central PMCID:
PMC5135310.
Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.
ACS Med Chem Lett.
2016 Oct 13;7(10):908-912. doi: 10.1021/acsmedchemlett.6b00209. eCollection 2016 Oct 13. PubMed PMID:
27774127; PubMed Central PMCID:
PMC5066161.
Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.
Elife.
2016 Oct 4;5. doi: 10.7554/eLife.17635. PubMed PMID:
27700986; PubMed Central PMCID:
PMC5050018.
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.
Cell Discov.
2016;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016. PubMed PMID:
27672444; PubMed Central PMCID:
PMC5029543.
What would you like to do?